KNSA · Kiniksa Pharmaceuticals International Plc
United States · RS rating 98 · As of 2026-10-14
| Price | 78.84 USD |
|---|---|
| 1-day change | +0.4% |
| RS rating (overall / 1M / 3M / 12M) | 98 / 89 / 93 / 96 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 50 / 58 / 50 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -26.1% |
| Sales growth Q/Q | +11.8% |
| Distance from 52-week high | +2.6% |
| Market cap (USD) | $3.3B |